Boothbay Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Boothbay Fund Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-114,700	Closed	-$5.34M	–	2141
2025 Q4	$5.34M	Buy	+114,700	New	+$5.11M	0.08%	272
2024 Q2	–	Sell	-87,700	Closed	-$4.11M	–	1584
2024 Q1	$4.11M	Buy	+87,700	New	+$3.43M	0.08%	288
2023 Q4	–	Sell	-92,700	Closed	-$2.76M	–	1704
2023 Q3	$2.76M	Buy	+92,700	New	+$1.91M	0.07%	395

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boothbay Fund Management's CRNX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 30,418 shares — an estimated $1.35M sold.

Boothbay Fund Management first reported a position in CRNX in Q2 2020 and held it in 11 quarters. The position peaked at $7.61M in Q1 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Boothbay Fund Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 30,418 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $1.35M.
Boothbay Fund Management first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 11 quarters.
Boothbay Fund Management's Crinetics Pharmaceuticals position peaked at $7.61M in Q1 2024.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.